tbuckley/cabot-search huggingface dataset:
Selection and prioritization of candidate combination regimens for the treatment of tuberculosis
Authors: Natasha Strydom, Rob C. van Wijk, Qianwen Wang, Jacqueline P. Ernest, Linda Chaba, Ziran Li, Eric L. Nuermberger, Radojka M. Savic
Journal: Science Translational Medicine (2025)

Accelerated tuberculosis drug discovery has increased the number of plausible multidrug regimens. Testing every drug combination in vivo is impractical, and varied experimental conditions make it challenging to compare results between experiments. Using published treatment efficacy data from a mouse tuberculosis model treated with candidate combination regimens, we trained and externally validated integrative mathematical models to predict relapse in mice and to rank both previously experimentally studied and unstudied regimens by their sterilization potential. We generated 18 datasets of 18 candidate regimens (comprising 11 drugs of six classes, including fluoroquinolone, nitroimidazole, diarylquinolines, and oxazolidinones), with 2965 relapse and 1544 colony-forming unit (CFU) observations for analysis. Statistical and machine learning techniques were applied to predict the probability of relapse in mice. The locked down mathematical model had an area under the receiver operating characteristic curve (AUROC) of 0.910 and showed that bacterial kill measured by longitudinal CFU cannot account for relapse alone and that sterilization is drug dependent. The diarylquinolines had the highest predicted sterilizing activity in the mouse model, and the addition of pyrazinamide to drug regimens provided the shortest estimated tuberculosis treatment duration to cure in mice. The mathematical model predicted the effect of treatment combinations, and these predictions were validated by conducting 11 experiments on previously unstudied regimens, achieving an AUROC of 0.829. We surmise that the next generation of tuberculosis drugs are highly effective at treatment shortening and suggest that there are several promising three- and four-drug regimens that should be advanced to clinical trials.
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
Authors: Luciano J. Costa, Eva Medvedova, Binod Dhakal, Bhagirathbhai R. Dholaria, Kelly N. Godby, Susan Bal, Gayathri Ravi, Smith Giri, Saurabh Chhabra, Rebecca Silbermann, Natalie S. Callander
Journal: Blood Cancer Journal (2025)
Medium- and Distal-Vessel Occlusion — The Limit of Thrombectomy?
Authors: J Mocco
Journal: New England Journal of Medicine (2025)

Few procedures have gone through a decade of practice-changing clinical trials as impressive as thrombectomy for stroke. Beginning in 2015 with multiple trials showing a benefit with thrombectomy in early large-vessel occlusion, followed by the extended-window trials in 2018 and then the large core trials in 2023, it seemed that no corner of the cerebrovasculature would not have a substantial benefit from a proper clot removal — until now. The ESCAPE-MeVO (Endovascular Treatment to Improve Outcomes for Medium Vessel Occlusions) trial1 and DISTAL (Endovascular Therapy plus Best Medical Treatment [BMT] versus BMT Alone for Medium Vessel Occlusion Stroke — A . . .
Author Correction: Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission
Authors: Nomonde Bengu, Gabriela Cromhout, Emily Adland, Katya Govender, Nicholas Herbert, Nicholas Lim, Rowena Fillis, Kenneth Sprenger, Vinicius Vieira, Samantha Kannie, Jeroen van Lobenstein, Kogielambal Chinniah, Constant Kapongo, Roopesh Bhoola, Malini Krishna, Noxolo Mchunu, Giuseppe Rubens Pascucci, Nicola Cotugno, Paolo Palma, Alfredo Tagarro, Pablo Rojo, Julia Roider, Maria C. Garcia-Guerrero, Christina Ochsenbauer, Andreas Groll, Kavidha Reddy, Carlo Giaquinto, Paolo Rossi, Seohyun Hong, Krista Dong, M. Azim Ansari, Maria C. Puertas, Thumbi Ndung’u, Edmund Capparelli, Mathias Lichterfeld, Javier Martinez-Picado, John C. Kappes, Moherndran Archary, Philip Goulder
Journal: Nature Medicine (2025)
Tracking pandemic pathogens from wastewater surveillance in international airports: Klebsiella pneumoniae ST16 coproducing NDM-4 and OXA-181 arriving in South America
Authors: Rubens R Sousa-Carmo, Johana Becerra, Elder Sano, Herrison Fontana, Thais Martins-Gonçalves, Gustavo Queiroga, Bruna Fuga, Renan L O Silva, Mikaela R F Barbosa, Maria Inês Z Sato, Nilton Lincopan
Journal: The Lancet Microbe (2025)
Coil or Plug-Assisted Retrograde transvenous obliteration (CARTO/PARTO) for treating portal hypertensive variceal bleeding: A multi-center, real-world 10-year retrospective study
Authors: Edward Wolfgang Lee, Sammy Saab, Navid Eghbalieh, Peng-xu Ding, Ung Bae Jeon, Joon Young Ohm, Ronnie C. Chen, Man-Deuk Kim, Kichang Han, Dong Jae Shim, Jong Soo Shin, Anirudh Mirakhur, Chien-An Liu, Jonathan Park, Frank Hao, Man Wong, Antonio Moreno, Jasleen Singh, Fady Kaldas, Douglas G. Farmer, Juan Gonzalez-Abraldes
Journal: Hepatology (2025)

Background &amp; Aims: CARTO and PARTO are well-accepted treatment for gastric variceal (GV) bleeding. However, long-term (&gt;2 years) clinical outcomes have yet to be studied. In this study, we investigated long-term clinical outcomes, including overall survival (OS) in 10 years Methods: We performed a multi-national, multi-center, retrospective study of CARTO/PARTO in GV treatments between 05/2012 and 07/2024. The primary study outcomes were a long-term OS and prognostic factors of CARTO/PARTO. The secondary outcomes were long-term clinical/technical success, complications, clinical changes including portal hypertensive symptoms. Results: A total of 311 patients (41% female; 69% CARTO) from 13 centers in five countries were included. The cumulative 1-, 3-, 5-, 7-, and 10-year OS rates were 98, 80, 68, 52, and 33%, respectively, with a median OS of 99 months. Prophylactic CARTO/PARTO showed a better OS than CARTO/PARTO for active bleeding ( p =0.00035). The independent prognostic factors of OS were having high pre-MELD, concurrent HCC, treating GOV2, history of esophageal variceal bleeding, high pre-TBili, and ammonia levels. Notably, a high pre-MELD score &gt;27 had a significantly higher mortality rate (92.6%) than a lower pre-MELD score ( p &lt;0.001). The overall cumulative 1-, 3-, 5-, 7-, and 10-year recurrent GV bleeding rates were 0.9, 3.2, 4.0, 4.5, and 5.4%, respectively. The overall technical and clinical success rates were 96.5% and 95.3%, respectively, with a 4.5% major complication rate over 10 years. Conclusions: CARTO and PARTO have excellent long-term survival and clinical outcomes. However, these are negatively affected by high MELD scores, concomitant HCC, and coexisting esophageal varices.
Estimation of respiratory syncytial virus-associated hospital admissions in five European countries: a modelling study
Authors: Caroline Klint Johannesen, David Gideonse, Richard Osei-Yeboah, Toni Lehtonen, Ombeline Jollivet, Rachel A Cohen, Arantxa Urchueguía-Fornes, María Herrero-Silvestre, Mónica López-Lacort, Rolf Kramer, Thea K Fischer, Terho Heikkinen, Harish Nair, Harry Campbell, Michiel van Boven
Journal: The Lancet Regional Health - Europe (2025)
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in <i>TP53</i>
Authors: Karlo Perica, Nayan Jain, Michael Scordo, Ruchi Patel, Ozgur Can Eren, Utsav Patel, Gunes Gundem, Dylan Domenico, Sneha Mitra, Nicholas D. Socci, John K. Everett, Aoife M. Roche, Angelina Petrichenko, Gunjan L. Shah, Maria E. Arcila, Laetitia Borsu, Jae H. Park, Steven M. Horwitz, Sergio A. Giralt, Ahmet Dogan, Christina Leslie, Elli Papaemmanuil, Frederic D. Bushman, Saad Z. Usmani, Michel Sadelain, Sham Mailankody
Journal: New England Journal of Medicine (2025)

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case of a T-cell lymphoma harboring a lentiviral integration in a known tumor suppressor, TP53, which developed in a patient with multiple myeloma after B-cell maturation antigen (BCMA) CAR T-cell therapy.
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive Cancer
Authors: Alison M. Schram, Koichi Goto, Dong-Wan Kim, Teresa Macarulla, Antoine Hollebecque, Eileen M. O’Reilly, Sai-Hong Ignatius Ou, Jordi Rodon, Sun Young Rha, Kazumi Nishino, Michaël Duruisseaux, Joon Oh Park, Cindy Neuzillet, Stephen V. Liu, Benjamin A. Weinberg, James M. Cleary, Emiliano Calvo, Kumiko Umemoto, Misako Nagasaka, Christoph Springfeld, Tanios Bekaii-Saab, Grainne M. O’Kane, Frans Opdam, Kim A. Reiss, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Shola Adeyemi, Lokesh Jain, Shekeab Jauhari, Alexander Drilon
Journal: New England Journal of Medicine (2025)

Neuregulin 1 (NRG1) fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to heterodimerization with HER2 and activation of downstream growth and proliferation pathways. The efficacy and safety of zenocutuzumab, a bispecific antibody against HER2 and HER3, in patients with NRG1 fusion-positive solid tumors are unclear. In this registrational, phase 2 clinical study, we assigned patients with advanced NRG1 fusion-positive cancer involving any tumor type to receive zenocutuzumab at a dose of 750 mg intravenously every 2 weeks. The primary end point was overall response (complete or partial response) according to investigator assessment. Secondary end points included duration of response, progression-free survival, and safety. A total of 204 patients with 12 tumor types were enrolled and treated. Among 158 patients who had measurable disease and were enrolled at least 24 weeks before the data-cutoff date, a response occurred in 30% (95% confidence interval [CI], 23 to 37). The median duration of response was 11.1 months (95% CI, 7.4 to 12.9); 19% of responses were ongoing at the data-cutoff date. Responses were observed in multiple tumor types - including in 27 of 93 patients (29%; 95% CI, 20 to 39) with non-small-cell lung cancer (NSCLC) and 15 of 36 patients (42%; 95% CI, 25 to 59) with pancreatic cancer - and across multiple NRG1 fusion partners. The median progression-free survival was 6.8 months (95% CI, 5.5 to 9.1). Adverse events were primarily grade 1 or 2. The most common adverse events that were considered by the investigator to be related to zenocutuzumab were diarrhea (in 18% of the patients), fatigue (in 12%), and nausea (in 11%). Infusion-related reactions (composite term) were observed in 14% of the patients. One patient discontinued zenocutuzumab owing to a treatment-related adverse event. Zenocutuzumab showed efficacy in patients with advanced NRG1 fusion-positive cancer, notably NSCLC and pancreatic cancer, with mainly low-grade adverse events. (Funded by Merus; eNRGy ClinicalTrials.gov number, NCT02912949.).
Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman’s Disease
Authors: Melanie D. Mumau, Michael V. Gonzalez, Chunyu Ma, Abiola H. Irvine, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Luke Y. C. Chen, David Koslicki, David C. Fajgenbaum
Journal: New England Journal of Medicine (2025)
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Authors: Jennifer R Brown, John F Seymour, Wojciech Jurczak, Andrew Aw, Malgorzata Wach, Arpad Illes, Alessandra Tedeschi, Carolyn Owen, Alan Skarbnik, Daniel Lysak, Ki-Seong Eom, Martin Šimkovič, Miguel Arturo Pavlovsky, Arnon Philip Kater, Barbara Eichhorst, Kara Miller, Veerendra Munugalavadla, Ting Yu, Marianne de Borja, Paolo Ghia
Journal: New England Journal of Medicine (2025)

BackgroundWhether fixed-duration acalabrutinib–venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown.MethodsIn this phase 3, open-label trial, we included patients 18 years of age or older who had an Eastern Cooperative Oncology Group performance-status score of 0 to 2 (range, 0 to 5, with higher numbers indicating greater disability) and who did not have a 17p deletion or TP53 mutation. Patients were randomly assigned, in a 1:1:1 ratio, to receive acalabrutinib–venetoclax (acalabrutinib, cycles 1 to 14; venetoclax, cycles 3 to 14), acalabrutinib–venetoclax–obinutuzumab (as above, plus obinutuzumab, cycles 2 to 7), or chemoimmunotherapy with the investigator's choice of fludarabine–cyclophosphamide–rituximab or bendamustine–rituximab (cycles 1 to 6). The primary end point was progression-free survival (acalabrutinib–venetoclax vs. chemoimmunotherapy) in the intention-to-treat population, assessed by blinded independent central review.ResultsA total of 867 patients underwent randomization: 291 were assigned to receive acalabrutinib–venetoclax, 286 acalabrutinib–venetoclax–obinutuzumab, and 290 chemoimmunotherapy (of whom 143 received fludarabine–cyclophosphamide–rituximab and 147 bendamustine–rituximab). The median age of the patients was 61 years (range, 26 to 86), 64.5% were men, and 58.6% had unmutated IGHV. Estimated 36-month progression-free survival at a median follow-up of 40.8 months was 76.5% with acalabrutinib–venetoclax, 83.1% with acalabrutinib–venetoclax–obinutuzumab, and 66.5% with chemoimmunotherapy (hazard ratio for disease progression or death with acalabrutinib–venetoclax vs. chemoimmunotherapy, 0.65 [95% confidence interval {CI}, 0.49 to 0.87], P=0.004; for the comparison of acalabrutinib–venetoclax–obinutuzumab with chemoimmunotherapy, P<0.001). Estimated 36-month overall survival was 94.1% with acalabrutinib–venetoclax, 87.7% with acalabrutinib–venetoclax–obinutuzumab, and 85.9% with chemoimmunotherapy. Neutropenia, the most common adverse event of clinical interest of grade 3 or higher, was reported in 32.3%, 46.1%, and 43.2% in the three groups, respectively; death from coronavirus disease 2019 was reported in 10, 25, and 21 patients in the three groups.ConclusionsAcalabrutinib–venetoclax with or without obinutuzumab significantly prolonged progression-free survival as compared with chemoimmunotherapy in fit patients with previously untreated CLL. (Funded by AstraZeneca; AMPLIFY ClinicalTrials.gov number, NCT03836261.)
STAT6 mutations compensate for CREBBP mutations and hyperactivate IL4/STAT6/RRAGD/mTOR signaling in follicular lymphoma
Authors: Qiangqiang Shao, Karan Bedi, Isabella A. Malek, Kerby Shedden, Sami N. Malek
Journal: Leukemia (2025)

Abstract Activating mutations in STAT6 are common in Follicular Lymphoma (FL) and transformed FL and various other B cell lymphomas. Here, we report RNA-seq based gene expression data on normal human lymph node derived B lymphocytes (NBC; N = 6), and primary human FL WT ( N = 11) or mutant ( N = 4) for STAT6 before and after ex vivo stimulation with IL4. We found that STAT6 mutants result in broad based augmentation of IL4-induced gene expression. Unexpectedly, in FL with WT STAT6 we measured reduced baseline and IL4-induced gene expression levels when compared with NBC lymphocytes or FL with STAT6 mutations. We tracked the attenuated IL4/JAK/STAT6 response to co-existing CREBBP mutations and experimentally verified that intact CREBBP is required for the induction of many IL4-induced genes. One of the IL4-induced genes here identified is RRAGD , a small G-protein involved in lysosomal mTOR activation. We show that IL4 treatment induced RRAGD expression, that RRAGD is required for mTOR activation in lymphoma cells and that IL4-enhanced BCR signaling induced mTOR activation. The IL4 and BCR-induced mTOR activation was reduced by CREBBP mutants and augmented by mutant STAT6, establishing a link between STAT6 mutations and mTOR regulated pro-growth pathways in lymphoma.
Dual-target nanotherapy for vascular endothelium and bone mesenchymal stem cells halt steroid-induced osteonecrosis of the femoral head progression
Authors: Wenbo Yang, Qing Pan, Yizhong Peng, Yuxiang Hu, Yongzhi Cui, Zengwu Shao, Chunqing Meng, Hong Wang, Wei Huang
Journal: Journal of Controlled Release (2025)
Multiple large language models versus experienced physicians in diagnosing challenging cases with gastrointestinal symptoms
Authors: Xintian Yang, Tongxin Li, Han Wang, Rongchun Zhang, Zhi Ni, Na Liu, Huihong Zhai, Jianghai Zhao, Fandong Meng, Zhongyin Zhou, Shanhong Tang, Limei Wang, Xiangping Wang, Hui Luo, Gui Ren, Linhui Zhang, Xiaoyu Kang, Jun Wang, Ning Bo, Xiaoning Yang, Weijie Xue, Xiaoyin Zhang, Ning Chen, Rui Guo, Baiwen Li, Yajun Li, Yaling Liu, Tiantian Zhang, Shuhui Liang, Yong Lv, Yongzhan Nie, Daiming Fan, Lina Zhao, Yanglin Pan
Journal: npj Digital Medicine (2025)

Abstract Faced with challenging cases, doctors are increasingly seeking diagnostic advice from large language models (LLMs). This study aims to compare the ability of LLMs and human physicians to diagnose challenging cases. An offline dataset of 67 challenging cases with primary gastrointestinal symptoms was used to solicit possible diagnoses from seven LLMs and 22 gastroenterologists. The diagnoses by Claude 3.5 Sonnet covered the highest proportion (95% confidence interval [CI]) of instructive diagnoses (76.1%, [70.6%–80.9%]), significantly surpassing all the gastroenterologists ( p &lt; 0.05 for all). Claude 3.5 Sonnet achieved a significantly higher coverage rate (95% CI) than that of the gastroenterologists using search engines or other traditional resource (76.1% [70.6%–80.9%] vs. 45.5% [40.7%-50.4%], p &lt; 0.001). The study highlights that advanced LLMs may assist gastroenterologists with instructive, time-saving, and cost-effective diagnostic scopes in challenging cases.
CD4 <sup>+</sup> T Cells Expressing Viral Proteins Induce HIV-Associated Endothelial Dysfunction and Hypertension Through Interleukin 1α–Mediated Increases in Endothelial NADPH Oxidase 1
Authors: Taylor C. Kress, Candee T. Barris, Laszlo Kovacs, Beryl N. Khakina, Coleton R. Jordan, Thiago Bruder-Nascimento, David W. Stepp, Rodger MacArthur, Vijay S. Patel, Jie Chen, Rafal Pacholczyk, Simone Kennard, Eric J. Belin de Chantemèle
Journal: Circulation (2025)

BACKGROUND: Although combination antiretroviral therapy has increased life expectancy in people living with HIV, it has led to a marked increase in the prevalence of hypertension, the cause of which is unknown. Despite combination antiretroviral therapy, HIV-derived proteins remain expressed and produced by CD4 + T lymphocytes in people living with HIV. However, their contribution to HIV-associated hypertension and impaired endothelium-dependent relaxation remains ill defined. METHODS: Here, we tested the hypothesis that CD4 + T cells expressing viral proteins contribute to endothelial dysfunction and hypertension using the Tg26 mouse model of HIV that expresses 7 of the 9 HIV proteins under the long terminal repeat promoter. We used male and female mice, bone marrow transplantation (BMT), adoptive transfer of CD4 + T cells, and aorta specimen discarded from people living with HIV. RESULTS: We reported that intact Tg26 mice and mice receiving BMT (Tg26→WT) or CD4 + T cells from Tg26 mice display impaired endothelium-dependent relaxation and hypertension. Conversely, BMT from WT mice into Tg26 mice, inhibition of T cell activation, and CD4 + T cell depletion restored endothelial function and blood pressure in Tg26 mice. Cytokine profiling revealed that Tg26 mice, Tg26→WT, and Tg26 CD4 + T cells consistently exhibit high interleukin 1α (IL-1α) levels with no significant increase in other cytokines, whereas BMT from WT mice into Tg26 mice reduced IL-1α levels. IL-1α neutralization reduced blood pressure and restored endothelial function in Tg26 mice. To investigate the role of CD4 + T cells and IL-1α in endothelial dysfunction, we developed an aorta-immune cell coculture system. Exposure of WT aortas to Tg26 CD4 + T cells impaired endothelium-dependent relaxation, which was blocked by IL-1α–neutralizing antibody. While investigating the mechanisms of endothelial dysfunction, we reported that Tg26 mice, Tg26→WT aorta exhibit high NADPH oxidase (NOX) 1 expression. IL-1α exposure increased NOX1 in human microvascular endothelial cells, and NOX1 blockade restored endothelial function in Tg26 and Tg26→WT arteries, whereas NOX1 deficiency protected against Tg26 BMT-induced impaired endothelium-dependent relaxation and hypertension. Aortas from people living with HIV exhibit high NOX1 levels, and exposure of human aorta to Tg26 T cells increased NOX1 expression. CONCLUSIONS: We provide the first evidence that CD4 + T cells expressing HIV viral proteins induced hypertension through IL-1α–mediated increases in vascular NOX1, which impairs endothelial function in males and females.
Efficacy of Irbesartan in Celiprolol-Treated Patients With Vascular Ehlers-Danlos Syndrome
Authors: Xavier Jeunemaitre, Elie Mousseaux, Michael Frank, Salma Adham, Francesca Pitocco, Clarisse Billon, Molka Ben Yakhlef, Mohamed El Hachmi, Alessandra Bura-Rivière, François-Xavier Lapébie, Claire Le Hello, Damien Laneelle, Christophe Seinturier, Klaus Dieterich, Marc Lambert, Sophie Dupuis-Girod, Stéphane Zuily, Laurence Bal-Theoleyre, Carine Boulon, Pierrick Henneton, Estelle Lu, Nicolas Denarié, Pierre Boutouyrie, Tristan Mirault, Gilles Chatellier, Michel Azizi
Journal: Circulation (2025)

BACKGROUND: Vascular Ehlers-Danlos syndrome is a rare genetic disorder characterized by defective type III collagen and a high risk of arterial morbidity and mortality. Several cardiovascular drugs are used for treatment, including celiprolol, but no controlled trial in this condition has been conducted to date. We hypothesized the benefit of the addition of an angiotensin II receptor blocker. METHODS: A multicenter, randomized, placebo-controlled trial was conducted to assess the efficacy and safety of the angiotensin II receptor blocker irbesartan in adults with vascular Ehlers-Danlos syndrome on stable background celiprolol therapy. Patients were randomized 1:1 to receive irbesartan (150 mg/day titrated to 300 mg/day) or placebo for 2 years. The composite primary outcome was defined as any vascular Ehlers-Danlos syndrome–related fatal or nonfatal arterial event or any new or worsening arterial lesions detected by systematic head-to-pelvis computed tomography angiography or peripheral arterial duplex ultrasound at different time points, using a time-to-first-event analysis. RESULTS: Twenty-nine participants (62% female; 40.3±11.3 years of age) were randomized to irbesartan, and 28 (64% female; 40.7±11.0 years of age) were randomized to placebo. The composite primary outcome occurred in 8 of 29 patients (27.6%) receiving irbesartan versus 15 of 28 patients (53.6%) receiving placebo (hazard ratio, 0.42 [95% CI, 0.17, 0.99]; P &lt;0.05). The risk of recurrent symptomatic or nonsymptomatic arterial events was lower with irbesartan than with placebo (risk ratio, 0.37 [95% CI, 0.19, 0.68]; P =0.002). A reduction of progression of arterial lesions was observed at all sites. Irbesartan significantly reduced systolic blood pressure compared with placebo (baseline-adjusted difference of 5.4 mm Hg [ P &lt;0.001]), but no relation was observed with the reduction of the primary composite outcome. Eleven episodes of irbesartan-related hypotension were recorded, leading to a downtitration in 4 patients. CONCLUSIONS: Compared with placebo, irbesartan reduced the risk of severe symptomatic and asymptomatic arterial events in patients with vascular Ehlers-Danlos syndrome on background celiprolol therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02597361.
First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy
Authors: Genís Prat-Ortega, Scott Ensel, Serena Donadio, Luigi Borda, Amy Boos, Prakarsh Yadav, Nikhil Verma, Jonathan Ho, Erick Carranza, Sarah Frazier-Kim, Daryl P. Fields, Lee E. Fisher, Doug J. Weber, Jeffrey Balzer, Tina Duong, Steven D. Weinstein, Mikael J. L. Eliasson, Jacqueline Montes, Karen S. Chen, Paula R. Clemens, Peter Gerszten, George Z. Mentis, Elvira Pirondini, Robert M. Friedlander, Marco Capogrosso
Journal: Nature Medicine (2025)